Angiogenesis is one hallmark of cancer. Vascular endothelial growth factor (VEGF) is a known inducer of angiogenesis. Many patients benefit from antiangiogenic therapies, which however have limitations. Although VEGF is overexpressed in most tumors, different VEGF isoforms with distinct angiogenic properties are produced through alternative splicing. In podocytes, the Wilms' tumor suppressor 1 (WT1) suppresses the Serine/arginine-rich protein-specific splicing factor kinase (SRPK1), and indirectly Serine/arginine-rich splicing factor 1 (Srsf1) activity, and alters VEGF splicing. We analyzed VEGF isoforms, Wt1, Srpk1, and Srsf1 in normal and tumor endothelium. Wt1, Srpk1, Srsf1, and the angiogenic VEGF164a isoform were highly expressed in tumor endothelium compared to normal lung endothelium. Nuclear expression of Srsf1 was detectable in the endothelium of various tumor types, but not in healthy tissues. Inducible conditional vessel-specific knockout of Wt1 reduced Wt1, Srpk1, and Srsf1 expression in endothelial cells and induced a shift towards the antiangiogenic VEGF120 isoform. Wt1(-KTS) directly binds and activates both the promoters of Srpk1 and Srsf1 in endothelial cells. In conclusion, Wt1 activates Srpk1 and Srsf1 and induces expression of angiogenic VEGF isoforms in tumor endothelium.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356959PMC
http://dx.doi.org/10.3390/cells8010041DOI Listing

Publication Analysis

Top Keywords

srpk1 srsf1
24
tumor endothelium
16
vegf isoforms
12
wt1 srpk1
12
vegf splicing
8
srsf1
8
wilms' tumor
8
tumor suppressor
8
suppressor wt1
8
splicing factor
8

Similar Publications

Aberrant FAM135B attenuates the efficacy of chemotherapy in colorectal cancer by modulating SRSF1-mediated alternative splicing.

Oncogene

November 2024

Department of Pathology, Guangdong Province Key Laboratory of Molecular Tumor Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.

Article Synopsis
  • * The gene FAM135B is frequently mutated in CRC, plays a key role in cancer cell growth, and contributes to the resistance against oxaliplatin by influencing a process called alternative splicing through the protein SRSF1.
  • * Targeting FAM135B could be a promising new approach to improve treatment outcomes for patients with colorectal cancer.
View Article and Find Full Text PDF
Article Synopsis
  • Cholangiocarcinoma (CCA) is a bile duct cancer prevalent in Thailand, characterized by poor prognosis and low survival rates due to challenges in early detection and treatment.
  • The study explores the role of serine/arginine protein kinases (SRPKs) in CCA, specifically how their hyperphosphorylation affects splicing factors linked to cancer-related mRNA errors.
  • Results indicate that high levels of SRPK1 correlate with shorter patient survival and that SRPK inhibitors increase cell death in CCA cell lines, revealing potential targets for new treatments.
View Article and Find Full Text PDF

Epsilon toxin (ETX), a potential agent of biological and toxic warfare, causes the death of many ruminants and threatens human health. It is crucial to understand the toxic mechanism of such a highly lethal and rapid course toxin. In this study, we detected the effects of ETX on the proteome and phosphoproteome of MDCK cells after 10 min and 30 min.

View Article and Find Full Text PDF
Article Synopsis
  • Regulation of alternative splicing, specifically of the PD-1 receptor, shows promise as a new therapeutic strategy in cancer treatment by enhancing T cell function against tumors.
  • Researchers conducted several experiments, including PCR and flow cytometry, to explore how splicing of PD-1 affects T cell response in the presence of cancer cells.
  • Findings revealed that a specific soluble variant of PD-1 (∆Ex3PD1) can inhibit cancer cell-induced T cell suppression, suggesting that manipulating splicing pathways could lead to novel immunotherapies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!